MOLN News and Press, Molecular Partners AG

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the &#...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the ...

2026-02-02 16:10:28 ET Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 February 2, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Molecular Partners AG (MOLN) Discusses...

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors MP0712 Phase 1/2a study op...

2026-01-27 06:15:11 ET H.C. Wainwright analyst issues BUY recommendation for MOLN on January 27, 2026 11:06AM ET. MOLN was trading at $4 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 3 - Hold recommend...

2026-01-15 17:16:01 ET Molecular Partners AG (MOLN) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Confe...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026 Phase 2 investigator-initiated trial of MP0317 now open with...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the ...

Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ...

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at basel...